| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Myristoleic acid (Oleomyristic Acid) is a naturally occurring cytotoxic agent from Serenoa repens with anticancer activity. It induces apoptosis and necrosis in human prostatic LNCaP cells. Myristoleic acid is capable of blocking the formation of large multinucleated osteoclasts and bone resorption likely through suppressing activation of Src and Pyk2.
| ln Vitro |
Myristoleic acid causes apoptosis in LNCaP cells (100 μg/mL, 89.5%) as well as necrosis (100 μg/mL, 81.8%)[1]. Particularly at later stages of differentiation, myristoleic acid inhibited the formation of osteoclasts induced by RANKL in vitro [2].
|
|---|---|
| ln Vivo |
Mice treated with myristoleic acid (2 mg/kg, IP every 24 h) for 4 days are able to avoid osteoclast development and bone loss caused by RANKL[2].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Human prostatic carcinoma LNCaP cells. Tested Concentrations: 0, 50, 100, 150, 200, 250 μg/mL. Incubation Duration: 24 h. Experimental Results: When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice at 5 weeks[2].
Doses: 0.2, 2 mg/kg Route of Administration: IP every 24 h for 4 days. Experimental Results: Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B . Pm and ES/BS in a dose-dependent manner. |
| References |
[1]. Xiaoyan Gao, et al. Ozone initiated heterogeneous oxidation of unsaturated carboxylic acids by ATR-FTIR spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2019 May 5;214:177-183.
[2]. Jun-Oh Kwon, et al. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2. Eur J Pharmacol. 2015 Dec 5;768:189-98. |
| Additional Infomation |
Myristoleic acid is a tetradecenoic acid in which the double bond is at the 9-10 position and has Z configuration. Myristoleic acid has been isolated from Serenoa repens and has cytotoxic and apoptosis-inducing effects. It has a role as an apoptosis inducer, a plant metabolite and an EC 3.1.1.1 (carboxylesterase) inhibitor. It is a tetradecenoic acid and a long-chain fatty acid. It is a conjugate acid of a myristoleate.
Myristoleic acid has been reported in Hoya crassipes, Hoya pseudolanceolata, and other organisms with data available. Myristoleic acid is a metabolite found in or produced by Saccharomyces cerevisiae. |
| Molecular Formula |
C14H26O2
|
|---|---|
| Molecular Weight |
226.36
|
| Exact Mass |
226.193
|
| CAS # |
544-64-9
|
| PubChem CID |
5281119
|
| Appearance |
Colorless to light yellow liquid（Density：0.9 g/cm3）
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
338.9±0.0 °C at 760 mmHg
|
| Melting Point |
-4.5--4ºC(lit.)
|
| Flash Point |
206.5±14.4 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.465
|
| LogP |
5.57
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
16
|
| Complexity |
185
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC/C=C\CCCCCCCC(=O)O
|
| InChi Key |
YWWVWXASSLXJHU-WAYWQWQTSA-N
|
| InChi Code |
InChI=1S/C14H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h5-6H,2-4,7-13H2,1H3,(H,15,16)/b6-5-
|
| Chemical Name |
(Z)-tetradec-9-enoic acid
|
| Synonyms |
cis-9-Tetradecenoate; Myristoleic Acid; Oleomyristic Acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~441.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4177 mL | 22.0887 mL | 44.1774 mL | |
| 5 mM | 0.8835 mL | 4.4177 mL | 8.8355 mL | |
| 10 mM | 0.4418 mL | 2.2089 mL | 4.4177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
